Replies to post #115508 on Biotech Values

[jq1234]

Today I actually addd to my position I accumulated during last summer, increasing my cost average a little bit. I was actually relieved there wasn't any major unknown issue from the plant cell based technology platform.

PS I have to mention one thing you despised, hedging with option saved me today, selling volatility in the past week when volatility spiked.

[mcbio]

Taliglucerase, once approved, may win at least 15 percent of patients “through strong marketing and competitive pricing,” said Ritu Baral, an analyst at Canaccord Genuity in New York, in a Feb. 22 note to clients.

Is 15% of the market really the consensus expected peak potential for this drug? I would think PFE wouldn't have bothered to get involved if they were only forecasting peak potential of 15% market share, especially since they will only be getting 60% of revenues.

[jq1234]

CRL for Gaucher's Drug; More Expenses Ahead for Protalix

http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=57492